YAP1 and head and neck squamous cell carcinoma: In addition, trametinib, an MAPK kinase (MEK) inhibitor, confers YAP overexpression and growth-related gene expression in HNSCC cell lines and patient-derived xenograft models, suggesting an effective combination therapy targeting YAP and MEK for HNSCC patients [136] (Figure 5).